Enzalutamide, a second-generation inhibitor of the AR-signaling pathway, has been approved by the U.S. Food and Drug Administration (FDA) to treat patients with castration-resistant or chemotherapy-resistant prostate cancer [23, 24]. Here, AR is linked to prostate cancer.